Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Retinoic Acid Receptors (RARs) Agonist development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportProvides a snapshot of the therapeutics pipeline activity for Retinoic Acid Receptors (RARs) Agonist Features the Retinoic Acid Receptors (RARs) Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Retinoic Acid Receptors (RARs) Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Retinoic Acid Receptors (RARs) Agonist
Reasons to BuyEstablish a comprehensive understanding of the current pipeline scenario across Retinoic Acid Receptors (RARs) Agonist to formulate effective R&D strategies Assess challenges and opportunities that influence Retinoic Acid Receptors (RARs) Agonist research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Retinoic Acid Receptors (RARs) Agonist Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Retinoic Acid Receptors (RARs) Agonist to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
1. Report Introduction
2. Retinoic Acid Receptors (RARs) Agonist - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Retinoic Acid Receptors (RARs) Agonist
4. Comparative Analysis
5. Retinoic Acid Receptors (RARs) Agonist Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Retinoic Acid Receptors (RARs) Agonist Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies FeaturedShionogi Syros Pharmaceuticals TMRC Co. Ltd. Allergan Galderma Clementia Pharmaceuticals Roche
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4jj2vp/retinoic_acid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005250/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/01/2019 07:54 AM/DISC: 02/01/2019 07:54 AM